Sign In
NASDAQ:AMRN
Amarin Corporation PLC Stock Earnings Reports
$0.415
+0.0012 (+0.290%)
At Close: Mar 17, 2025
Amarin PLC Earnings Calls
Q4 2024
Missed
-$0.120 (-100.00%)
| Release date | Mar 12, 2025 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.120 |
| EPS Surprise | -100.00% |
| Revenue estimate | 50.279M |
| Revenue actual | 62.306M |
| Revenue Surprise | 23.92% |
Q3 2024
| Release date | Oct 30, 2024 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0500 |
| Revenue estimate | 31.693M |
| Revenue actual | 42.298M |
| Revenue Surprise | 33.46% |
Q2 2024
Beat
$0.0100 (100.00%)
| Release date | Jul 31, 2024 |
| EPS estimate | $0.0050 |
| EPS actual | $0.0100 |
| EPS Surprise | 100.00% |
| Revenue estimate | 40.61M |
| Revenue actual | 67.567M |
| Revenue Surprise | 66.38% |
Q1 2024
Missed
-$0.0100 (-33.33%)
| Release date | May 01, 2024 |
| EPS estimate | -$0.0075 |
| EPS actual | -$0.0100 |
| EPS Surprise | -33.33% |
| Revenue estimate | 51.02M |
| Revenue actual | 56.487M |
| Revenue Surprise | 10.71% |
Last 4 Quarters for Amarin PLC
Below you can see how AMRN performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q1 2024
Missed
| Release date | May 01, 2024 |
| Fiscal end date | Mar 31, 2024 |
| Price on release | $0.84 |
| EPS estimate | -$0.0075 |
| EPS actual | -$0.0100 |
| EPS surprise | -33.33% |
| Date | Price |
|---|---|
| Apr 25, 2024 | $0.86 |
| Apr 26, 2024 | $0.87 |
| Apr 29, 2024 | $0.88 |
| Apr 30, 2024 | $0.92 |
| May 01, 2024 | $0.84 |
| May 02, 2024 | $0.92 |
| May 03, 2024 | $0.91 |
| May 06, 2024 | $0.98 |
| May 07, 2024 | $0.98 |
| 4 days before | -2.42% |
| 4 days after | 16.18% |
| On release day | 9.38% |
| Change in period | 13.37% |
Q2 2024
Beat
| Release date | Jul 31, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $0.682 |
| EPS estimate | $0.0050 |
| EPS actual | $0.0100 |
| EPS surprise | 100.00% |
| Date | Price |
|---|---|
| Jul 25, 2024 | $0.791 |
| Jul 26, 2024 | $0.796 |
| Jul 29, 2024 | $0.780 |
| Jul 30, 2024 | $0.783 |
| Jul 31, 2024 | $0.682 |
| Aug 01, 2024 | $0.621 |
| Aug 02, 2024 | $0.640 |
| Aug 05, 2024 | $0.654 |
| Aug 06, 2024 | $0.705 |
| 4 days before | -13.80% |
| 4 days after | 3.42% |
| On release day | -8.90% |
| Change in period | -10.86% |
Q3 2024
| Release date | Oct 30, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $0.602 |
| EPS estimate | -$0.0500 |
| EPS actual | -$0.0500 |
| Date | Price |
|---|---|
| Oct 24, 2024 | $0.575 |
| Oct 25, 2024 | $0.582 |
| Oct 28, 2024 | $0.634 |
| Oct 29, 2024 | $0.612 |
| Oct 30, 2024 | $0.602 |
| Oct 31, 2024 | $0.580 |
| Nov 01, 2024 | $0.586 |
| Nov 04, 2024 | $0.605 |
| Nov 05, 2024 | $0.623 |
| 4 days before | 4.73% |
| 4 days after | 3.49% |
| On release day | -3.74% |
| Change in period | 8.38% |
Q4 2024
Missed
| Release date | Mar 12, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $0.400 |
| EPS estimate | -$0.0600 |
| EPS actual | -$0.120 |
| EPS surprise | -100.00% |
| Date | Price |
|---|---|
| Mar 06, 2025 | $0.534 |
| Mar 07, 2025 | $0.530 |
| Mar 10, 2025 | $0.465 |
| Mar 11, 2025 | $0.470 |
| Mar 12, 2025 | $0.400 |
| Mar 13, 2025 | $0.410 |
| Mar 14, 2025 | $0.414 |
| Mar 17, 2025 | $0.415 |
| 4 days before | -25.12% |
| 4 days after | 3.72% |
| On release day | 2.47% |
| Change in period | -22.33% |
Amarin PLC Earnings Call Transcript Summary of Q4 2024
Financial Overview:
- Total net revenue for Q4 2024: $62.3 million (of which $60.1 million came from product sales).
- Year-end total revenue for 2024: $228.6 million.
- U.S. product revenue decreased significantly, falling from $64.9 million in Q4 2023 to $44.2 million, primarily due to:
- Generic competition
- Contract changes with CVS
- European product revenue increased to $4 million, driven by growth in Spain and the UK.
- Cash position at year-end: $294 million with no debt, reflecting effective cost management and operating efficiency.
Strategic Actions:
- Announced a change to the American Depositary Share (ADS) ratio from 1:1 to 1:20 to maintain NASDAQ listing by adhering to the minimum bid price.
- Aimed to enhance shareholder value and perception amidst undervaluation of Amarin's stock.
Global Expansion of VASCEPA:
- Approved in 49 markets globally, with access negotiations ongoing.
- Commercial launches in over 20 markets; further expansion into 16 additional countries is in progress.
- Significant opportunities identified, particularly in Europe, with IP protection extended to 2039 and high-risk patient populations.
Research and Development Updates:
- Focus on expanding the evidence base for VASCEPA, supporting over 500 publications since 2011.
- Continued regulatory filings, with 15 approvals for the REDUCE-IT indication in regions outside the U.S.
- New data to be presented at upcoming medical conferences highlighting VASCEPA's advantages alongside LDL-C lowering therapies.
Operational Strategy:
- Continued emphasis on operational discipline and cost management, achieving a 26% reduction in operating expenses year-over-year.
- Future priorities include maximizing the global potential of VASCEPA while remaining financially stable.
Market Trends and Opportunities:
- Rising demand for VASCEPA, especially in challenging markets like China and Australia.
- Ongoing focus on enhancing medical advocacy to drive usage within the medical community.
- Potential for leveraging partnerships to accelerate revenue growth in both established and emerging markets.
Concluding Remarks:
- Amarin remains committed to driving shareholder value and expanding VASCEPA's reach among at-risk patient populations globally.
- The focus will be on maintaining a strong financial position while executing a strategic growth plan in 2025.
- Investors are encouraged to consider the long-term potential of the company given the significant unmet need in cardiovascular health.
Amarin PLC Earnings History
Earnings Calendar
FAQ
When is the earnings report for AMRN?
Amarin Corporation PLC (AMRN) has scheduled its earnings report for May 07, 2025 before the markets open.
What is the AMRN price-to-earnings (P/E) ratio?
AMRN P/E ratio as of Mar 17, 2025 (TTM) is -2.08.
What is the AMRN EPS forecast?
The forecasted EPS (Earnings Per Share) for Amarin Corporation PLC (AMRN) for the first fiscal quarter 2025 is -$0.0600.
What are Amarin Corporation PLC's retained earnings?
On its balance sheet, Amarin Corporation PLC reported retained earnings of $62.31 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
